Your browser doesn't support javascript.
loading
The role of adjuvant treatment in early-stage oral cavity squamous cell carcinoma: An international collaborative study.
Fridman, Eran; Na'ara, Shorook; Agarwal, Jaiprakash; Amit, Moran; Bachar, Gideon; Villaret, Andrea Bolzoni; Brandao, Jose; Cernea, Claudio R; Chaturvedi, Pankaj; Clark, Jonathan; Ebrahimi, Ardalan; Fliss, Dan M; Jonnalagadda, Sashikanth; Kohler, Hugo F; Kowalski, Luiz P; Kreppel, Matthias; Liao, Chun-Ta; Patel, Snehal G; Patel, Rajan S; Robbins, K Thomas; Shah, Jatin P; Shpitzer, Thomas; Yen, Tzu-Chen; Zöller, Joachim E; Gil, Ziv.
Afiliação
  • Fridman E; Rambam Healthcare Campus, Technion-Israel Institute of Technology, Haifa, Israel.
  • Na'ara S; Laboratory for Applied Cancer Research, Technion-Israel Institute of Technology, Haifa, Israel.
  • Agarwal J; Rambam Healthcare Campus, Technion-Israel Institute of Technology, Haifa, Israel.
  • Amit M; Laboratory for Applied Cancer Research, Technion-Israel Institute of Technology, Haifa, Israel.
  • Bachar G; Tata Memorial Hospital, Mumbai, India.
  • Villaret AB; Rambam Healthcare Campus, Technion-Israel Institute of Technology, Haifa, Israel.
  • Brandao J; Laboratory for Applied Cancer Research, Technion-Israel Institute of Technology, Haifa, Israel.
  • Cernea CR; Department of Otolaryngology-Head and Neck Surgery, Rabin Medical Center, Petach Tikva, Israel.
  • Chaturvedi P; Ear, Nose, and Throat Department, University of Brescia, Brescia, Italy.
  • Clark J; Department of Head and Neck Surgery, University of São Paulo Medical School, São Paulo, Brazil.
  • Ebrahimi A; Department of Head and Neck Surgery, University of São Paulo Medical School, São Paulo, Brazil.
  • Fliss DM; Tata Memorial Hospital, Mumbai, India.
  • Jonnalagadda S; Sydney Head and Neck Cancer Institute, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Kohler HF; Department of Head and Neck Surgery, Liverpool Hospital, Sydney, New South Wales, Australia.
  • Kowalski LP; Sydney Head and Neck Cancer Institute, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Kreppel M; Department of Head and Neck Surgery, Liverpool Hospital, Sydney, New South Wales, Australia.
  • Liao CT; University of New South Wales, Sydney, New South Wales, Australia.
  • Patel SG; Department of Otolaryngology-Head and Neck Surgery, Tel Aviv Medical Center, Tel Aviv, Israel.
  • Patel RS; Southern Illinois University School of Medicine, Springfield, Illinois.
  • Robbins KT; Department of Head and Neck Surgery, A. C. Camargo Cancer Center, São Paulo, Brazil.
  • Shah JP; A. C. Camargo Cancer Center, São Paulo, Brazil.
  • Shpitzer T; Department of Oral and Cranio-Maxillo and Facial Plastic Surgery, University of Cologne, Cologne, Germany.
  • Yen TC; Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • Zöller JE; Head and Neck Surgery Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Gil Z; University of Auckland, Auckland, New Zealand.
Cancer ; 124(14): 2948-2955, 2018 07 15.
Article em En | MEDLINE | ID: mdl-29757457
ABSTRACT

BACKGROUND:

Up to half of patients with oral cavity squamous cell carcinoma (OCSCC) have stage I to II disease. When adequate resection is attained, no further treatment is needed; however, re-resection or radiotherapy may be indicated for patients with positive or close margins. This multicenter study evaluated the outcomes and role of adjuvant treatment in patients with stage I to II OCSCC.

METHODS:

Overall survival (OS), disease-specific survival, local-free survival, and disease-free survival rates were calculated with Kaplan-Meier analysis.

RESULTS:

Of 1257 patients with T1-2N0M0 disease, 33 (2.6%) had positive margins, and 205 (16.3%) had close margins. The 5-year OS rate was 80% for patients with clear margins, 52% for patients with close margins, and 63% for patients with positive margins (P < .0001). In a multivariate analysis, age, depth of invasion, and margins were independent predictors of outcome. Close margins were associated with a >2-fold increase in the risk of recurrence (P < .0001). The multivariate analysis revealed that adjuvant treatment significantly improved the outcomes of patients with close/positive margins (P = .002 to .03).

CONCLUSIONS:

Patients with stage I to II OCSCC and positive/close margins have poor long-term outcomes. For this population, adjuvant treatment may be associated with improved survival. Cancer 2018;1242948-55. © 2018 American Cancer Society.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Bucais / Margens de Excisão / Carcinoma de Células Escamosas de Cabeça e Pescoço / Recidiva Local de Neoplasia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Israel

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Bucais / Margens de Excisão / Carcinoma de Células Escamosas de Cabeça e Pescoço / Recidiva Local de Neoplasia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Israel